Search research articles
Contact Us
Filters
Showing results (31-40 of 132) with videos related to
Page
of 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
October 16, 2018
Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018
Jacopo Giuliani, Andrea Bonetti
Clinical Colorectal Cancer
|
March 19, 2018
Regorafenib or Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer? A Perspective on the Basis of Pharmacological Costs
Jacopo Giuliani, Andrea Bonetti
Journal of Medical Virology
|
August 12, 2020
Cancer prevales on COVID-19: To maintain high quality standard concerning diagnosis and oncological care even during a pandemic
Jacopo Giuliani, Andrea Bonetti
International Journal of Colorectal Disease
|
September 15, 2020
To perform genotyping of dihydropyrimidine dehydrogenase (DPD) before starting treatment with 5-fluorouracil or related medicines: really feasible?
Jacopo Giuliani, Andrea Bonetti
The Breast Journal
|
September 13, 2020
The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer is supported by clinical evidence
Jacopo Giuliani, Andrea Bonetti
European Urology
|
November 4, 2017
Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041: Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?
Jacopo Giuliani, Andrea Bonetti
Clinical Lung Cancer
|
June 2, 2016
The Pharmacological Costs for the Management of Skin Toxicity in Patients With Cancer Treated With Epidermal Growth Factor Receptor-Inhibitors
Jacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina
|
January 4, 2018
[La combinazione di gemcitabina e oxaliplatino (GEMOX) nel trattamento del carcinoma pancreatico in fase avanzata di malattia: le notizie sulla mia morte sono state esagerate?]
Jacopo Giuliani, Andrea Bonetti
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
November 21, 2013
Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate
Jacopo Giuliani, Andrea Bonetti
International Journal of Colorectal Disease
|
May 28, 2018
Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costs
Jacopo Giuliani, Andrea Bonetti
Page
of 14
Search research articles
Search
Showing results (31-40 of 132) with videos related to
Sort By:
Page
of 14
European Journal of Cancer (Oxford, England : 1990)
|
October 16, 2018
Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018
Jacopo Giuliani, Andrea Bonetti
Clinical Colorectal Cancer
|
March 19, 2018
Regorafenib or Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer? A Perspective on the Basis of Pharmacological Costs
Jacopo Giuliani, Andrea Bonetti
Journal of Medical Virology
|
August 12, 2020
Cancer prevales on COVID-19: To maintain high quality standard concerning diagnosis and oncological care even during a pandemic
Jacopo Giuliani, Andrea Bonetti
International Journal of Colorectal Disease
|
September 15, 2020
To perform genotyping of dihydropyrimidine dehydrogenase (DPD) before starting treatment with 5-fluorouracil or related medicines: really feasible?
Jacopo Giuliani, Andrea Bonetti
The Breast Journal
|
September 13, 2020
The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer is supported by clinical evidence
Jacopo Giuliani, Andrea Bonetti
European Urology
|
November 4, 2017
Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041: Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?
Jacopo Giuliani, Andrea Bonetti
Clinical Lung Cancer
|
June 2, 2016
The Pharmacological Costs for the Management of Skin Toxicity in Patients With Cancer Treated With Epidermal Growth Factor Receptor-Inhibitors
Jacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina
|
January 4, 2018
[La combinazione di gemcitabina e oxaliplatino (GEMOX) nel trattamento del carcinoma pancreatico in fase avanzata di malattia: le notizie sulla mia morte sono state esagerate?]
Jacopo Giuliani, Andrea Bonetti
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
November 21, 2013
Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate
Jacopo Giuliani, Andrea Bonetti
International Journal of Colorectal Disease
|
May 28, 2018
Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costs
Jacopo Giuliani, Andrea Bonetti
Page
of 14